The Nifty traded below the 26,050 mark. Pharma shares witnessed profit booking after advancing in the past three consecutive trading sessions.
At 14:30 IST, the barometer index, the S&P BSE Sensex, declined 100.20 points or 0.12% to 85,167.42. The Nifty 50 index lost 29.90 points or 0.11% to 26,019.45.
In the broader market, the S&P BSE Mid-Cap index rose 0.02% and the S&P BSE Small-Cap index advanced 0.38%.
The market breadth was positive. On the BSE, 2,172 shares rose and 2,013 shares fell. A total of 202 shares were unchanged.
Buzzing Index:
The Nifty Pharma index slipped 0.57% to 22,679. The index rallied 1.26% in the past three consecutive trading sessions.
Ipca Laboratories (down 1.56%), Piramal Pharma (down 1.51%), Mankind Pharma (down 1.41%), Lupin (down 1.19%), Divis Laboratories (down 1.03%), Ajanta Pharma (down 0.84%), Cipla (down 0.81%), Zydus Lifesciences (down 0.76%), J B Chemicals & Pharmaceuticals (down 0.73%) and Aurobindo Pharma (down 0.69%) declined.
Numbers to Track:
The yield on India's 10-year benchmark federal paper rose 0.11% to 6.603 compared with previous session close of 6.596.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 90.6950 compared with its close of 90.4950 during the previous trading session.
MCX Gold futures for 5 February 2025 settlement rose 1.30% to Rs 135,360.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was down 0.03% to 97.98.
The United States 10-year bond yield lost 0.48% to 4.175.
In the commodities market, Brent crude for February 2025 settlement added 13 cents or 0.21% to $61.25 a barrel.
Stocks in Spotlight:
SBC Exports rose 0.90%. The company announced that it has secured an order worth Rs 10.76 crore from the Indian Institute of Technology (IIT) Jodhpur for the supply of manpower.
Crest Ventures added 0.88%. The company said that its wholly owned subsidiary Crest Urban Living has entered into joint development agreement with Vensco Projects LLP for development of a premium mixed-use project in Chembur.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
